Sam Brusco, Associate Editor04.20.23
Treace Medical Concepts has filed 15 new patent applications in 2023, and the U.S. Patent and Trademark Office granted the company seven utility patents.
These granted patents are U.S. Patent Nos. 11,627,954, 11,622,797, 11,602,386, 11,602,387, 11,607,250, 11,596,443, and 11,583,323, relating to novel systems, devices, and methods to perform instrumented surgery for bunions and related deformities.
Treace now has a global IP portfolio of 58 granted patents, including 47 in the U.S. The company has 84 pending patent applications.
“We are pleased that patent offices around the world continue to recognize the novel innovations made by our company,” John T. Treace, CEO, founder and board member of Treace told the press. “Since we filed our first patents in 2014, we have continued to develop our product line and build upon our comprehensive intellectual property assets spanning the spectrum of multi-planar bunion correction.”
“Our intellectual property is a critical component in advancing patient care.” Treace added. “We have also secured trademarks and copyrights to protect our market leading brand. We remain committed to protecting and defending our proprietary technology and intellectual property, which drives our ability to innovate solutions that benefit patients.”
Treace also came to an amicable resolution with Fusion Orthopedics last month regarding previous litigation between the two companies.
These granted patents are U.S. Patent Nos. 11,627,954, 11,622,797, 11,602,386, 11,602,387, 11,607,250, 11,596,443, and 11,583,323, relating to novel systems, devices, and methods to perform instrumented surgery for bunions and related deformities.
Treace now has a global IP portfolio of 58 granted patents, including 47 in the U.S. The company has 84 pending patent applications.
“We are pleased that patent offices around the world continue to recognize the novel innovations made by our company,” John T. Treace, CEO, founder and board member of Treace told the press. “Since we filed our first patents in 2014, we have continued to develop our product line and build upon our comprehensive intellectual property assets spanning the spectrum of multi-planar bunion correction.”
“Our intellectual property is a critical component in advancing patient care.” Treace added. “We have also secured trademarks and copyrights to protect our market leading brand. We remain committed to protecting and defending our proprietary technology and intellectual property, which drives our ability to innovate solutions that benefit patients.”
Treace also came to an amicable resolution with Fusion Orthopedics last month regarding previous litigation between the two companies.